Fresh Tracks paused R&D in second quarter to ‘conserve capital’
BOULDER — Fresh Tracks Therapeutics Inc., which has spent the past few months mulling its merger and acquisition options, said in the second quarter of 2023 that it has “paused substantially all of its research and development activities in order to conserve capital resources during its ongoing evaluation of potential strategic options.”
That evaluation process “will dictate the company’s future path including to what extent the current pipeline continues to be developed.”
The R&D pause came at around the same time the company amended its 2022 asset purchase agreement with Botanix Pharmaceuticals Ltd. to give Botanix future profits from the sale…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
